South San Francisco,
This is an observational study designed to follow patients with metastatic or locally
advanced and unresectable colorectal cancer who are receiving Avastin in combination with
chemotherapy and whose cancer has been either previously untreated or treated <=4 months
prior to enrollment.
- Signed Informed Consent and Authorization document
- Metastatic, or locally advanced and unresectable, adenocarcinoma of the colon or
- Receiving Avastin as a component of first-line chemotherapy
- First-line chemotherapy plus Avastin initiated <=4 months prior to enrollment in the
- Patients who have contraindications for treatment with Avastin (see the Avastin
Package Insert) or who would incur excessive risks with Avastin treatment are
ineligible for this study.